Ra Medical Systems Raises $7.6 Million Through Completed At-The-Market Facility
Summary
“Proceeds from this offering help us meet the conditions of the proposed merger with Catheter Precision, and are another step toward bringing our shareholders the value of their groundbreaking electrophysiology technology to improve the treatment of cardiac arrhythmias,” said Will McGuire, Ra Medical CEO. If completed, the Merger will result in a combined publicly traded company that will focus on the cardiac electrophysiology market, one of the most robust and growing areas of medical devices. This communication contains forward-looking statements which include, but are not limited to, statements regarding expected timing, completion and effects of the proposed Merger, future access to capital markets, and the plans and expectations of the combined company regarding Catheter Precision’s products, including its plans, strategies, projected timelines and estimated markets, for and/or related to VIVO and the Amigo and vessel closure devices described above. If Ra Medical’s stock price drops below certain levels, the amount of merger consideration, if any, received by Catheter stockholders will be adversely impacted. The extent to which the COVID-19 pandemic impacts the Company’s and Catheter Precision’s businesses, operations, and financial results, including the duration and magnitude of such effects, will depend on numerous factors, which are unpredictable, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume.
Funding
Review available funding amount, funding date, investors, and linked company information related to Ra Medical Systems Raises $7.6 Million Through Completed At-The-Market Facility in the interactive ISVWorld profile.